Concepedia

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer

Robert O’Connor, Michael P. O’Leary, J. Ballot, Conor D. Collins, Paula Kinsella, Donald E. Mager, Robert D. Arnold, Lorraine O’Driscoll, A. Larkin, Susan Kennedy,

Cancer Chemotherapy and Pharmacology · 2006 · 63 citations · 22 references

DOI

Concepts

References

22

Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

S M Hsu, Laurence Raine, Herbert Fanger · Journal of Histochemistry & Cytochemistry · 1981 · 14.3K citations · Full text

, , +8

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

R. L. Juliano, Victor Ling · Biochimica et Biophysica Acta (BBA) - Biomembranes · 1976 · 3.3K citations

, , +11

Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line

Susan P.C. Cole, Gabu Bhardwaj, James H. Gerlach et al. · Science · 1992 · 3.1K citations

, , +16

Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.

Gary A. Piazza, A K Rahm, T S Finn et al. · PubMed · 1997 · 354 citations

, , +15

RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

Herman Burger, John A. Foekens, Maxime P. Look et al. · PubMed · 2003 · 293 citations · Full text

, , +17